ETS1 and breast carcinoma: In this study, we examined the effect of four PARPi, PJ‐34, ABT‐888, olaparib, and rucaparib in two breast cancer cell lines without BRCA mutation, Ets‐1‐expressing MDA‐MB‐231, and Ets‐1‐non‐expressing MCF‐7.